CLL resource hub

CLL videos

Dose Modifications for ARs: An APP Perspective

Lisa Nodzon, PhD, ARNP, AOCNP discusses IMBRUVICA® dose modifications guidance for certain ARs and her perspective based on real-world experience.
See dose modifications for ARs and data

Watch video

A Peer Perspective: Data, Including Long-Term Follow-Up

Lisa Nodzon, PhD, ARNP, AOCNP, shares her real-world experience treating patients with IMBRUVICA®.
See the data, including long-term follow-up data

Watch video

A Peer Perspective: NCCN Guidance on Dose Modifications for ARs1

Lisa Nodzon, PhD, ARNP, AOCNP, explores the clinical guidelines and how dose modifications for certain ARs with IMBRUVICA® can help your appropriate patients continue treatment.
Visit the dose modifications page

Discontinuation may be appropriate for some patients.

NCCN makes no warranties of any kind whatsoever regarding their content, use, or application, and disclaims any responsibility for their application or use in any way.

Watch video

IMBRUVICA® Dosing Video

Dosing information and outcomes in 1L CLL patients following dose modifications for adverse reactions.
Visit the CLL dosing page

Watch video

CLL codes & resources

Other IMBRUVICA® resources

Additional IMBRUVICA® resource hubs

Abbreviation

AR=adverse reaction.

Reference

1Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma V.2.2025. © National Comprehensive Cancer Network, Inc. 2025. All rights reserved. Accessed February 24, 2025. To view the most recent and complete version of the guideline, go online to NCCN.org